Dilpacimab
Based on 1 Customer Validation
Dilpacimab (ABT165) is a bispecific variable domain immunoglobulin. Dilpacimab binds to and inhibits DLL4 and VEGF and acts as a tumor growth inhibitor. Dilpacimab can be used in research related to metastatic colorectal cancer and advanced solid tumors.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.88%
- CAS No.: 1791420-09-1
- Masse moléculaire:199.12 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform VEGFR
More
Activité biologique
[VH-VH'-H-Gamma1_VL-VL'-C-kappa]-dimer
Human
VEGFA & DLL4
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
[VH-VH'-H-Gamma1_VL-VL'-C-kappa]-dimer
ELISA, FACS, Functional assay
-
Immobilized Delta-like protein 4/DLL4 Protein, Human can bind Dilpacimab. The EC50 for this effect is 5.82 ng/mL. -
Flow cytometric analysis of 1X106 HeLa cells with Dilpacimab (HY-P99852, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 1791420-09-1
-
Appearance Liquid
-
Masse moléculaire 199.12 kDa
-
Color Colorless to light yellow
-
SMILES
[Dilpacimab]
-
Synonyms
ABT165; PR1283233
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Strickler JH, et al. Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol. 2022;18(27):3011-3020. [Content Brief]
[2]. Gordon MS, et al. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2021;20(10):1988-1995. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)